EPISODE · May 18, 2021 · 7 MIN
The Asset Allocator: Intel’s Cure Precedes Its Illness
from SA For FAs · host Seeking Alpha
Intel’s detractors criticize the company for falling behind competitors in data-center sales, for reducing buybacks and for declining profit margins. But it is when a company is down that its stock price provides an attractive entry point. This podcast (8:05) argues that Intel’s problems are fixable and that its new leadership appears to be busy fixing them now. And in the meantime, its stock sells at a modest price-to-earnings ratio of 12, a fraction of the industry average.Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
Intel’s detractors criticize the company for falling behind competitors in data-center sales, for reducing buybacks and for declining profit margins. But it is when a company is down that its stock price provides an attractive entry point. This podcast (8:05) argues that Intel’s problems are fixable and that its new leadership appears to be busy fixing them now. And in the meantime, its stock sells at a modest price-to-earnings ratio of 12, a fraction of the industry average.Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
The Asset Allocator: Intel’s Cure Precedes Its Illness
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m